Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation

Journal of Clinical Investigation

Volumn 118, Issue 11, 2008, Pages 3629-3638

  Alliouachene, Samira ^a,b   Tuttle, Robyn L ^c   Boumard, Stephanie ^a,b   Lapointe, Thomas ^a,b   Berissi, Sophie ^a,b   Germain, Stephane ^d   Jaubert, Francis ^e   Tosh, David ^f   Birnbaum, Morris J ^c   Pende, Mario ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AKT1; PROTEIN KINASE B; S6 KINASE; S6 KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULINOMA; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; CELL SIZE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; INSULIN; INSULIN-SECRETING CELLS; INSULINOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREAS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBOSOMAL PROTEIN S6 KINASES;

EID: 55849111942     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35237     Document Type: Article

References (51)

1. Kulkarni, R.N. 2005. New insights into the roles of insulin/IGF-I in the development and maintenance of beta-cell mass. Rev. Endocr.Metab. Disord. 6:199-210.
2. Ueki, K., et al. 2006. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat. Genet. 38:583-588.
3. Withers, D.J., et al. 1999. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 23:32-40.
4. Pende, M., et al. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature. 408:994-997.
5. Tuttle, R.L., et al. 2001. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat. Med. 7:1133-1137.
6. Bernal-Mizrachi, E., Wen, W., Stahlhut, S., Welling, C.M., and Permutt, M.A. 2001. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J. Clin. Invest. 108:1631-1638.
7. Bhaskar, P.T., and Hay, N. 2007. The two TORCs and Akt. Dev.Cell. 12:487-502.
8. Harada, H., Andersen, J.S., Mann, M., Terada, N., and Korsmeyer, S.J. 2001. p70S6 kinase signals cell survival as well as growth, inactivating the proapoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 98:9666-9670.
9. Zhang, H.H., Lipovsky, A.I., Dibble, C.C., Sahin, M., and Manning, B.D. 2006. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell. 24:185-197.
10. Kim, D.H., et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110:163-175.
11. Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098-1101.
12. Um, S.H., et al. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 431:200-205.
13. Manning, B.D., and Cantley, L.C. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28:573-576.
14. Ma, L., et al. 2005. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19:1779-1786.
15. Manning, B.D., et al. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19:1773-1778.
16. Neshat, M.S., et al. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98:10314-10319.
17. +/- mice. Proc. Natl. Acad. Sci. U. S. A. 98:10320-10325.
18. Sarbassov, D.D., et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22:159-168.
19. Whiteman, E.L., Cho, H., and Birnbaum, M.J. 2002. Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13:444-451.
20. Vivanco, I., and Sawyers, C.L. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:489-501.
21. Luo, J., Manning, B.D., and Cantley, L.C. 2003. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 4:257-262.
22. Manning, B.D., and Cantley, L.C. 2007. AKT/PKB signaling: navigating downstream. Cell. 129:1261-1274.
23. Giordano, E., et al. 1993. B-cell size influences glucose-stimulated insulin secretion. Am. J. Physiol. 265:C358-C364.
24. Ohanna, M., et al. 2005. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7:286-294.
25. Rommel, C., et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013.
26. Sandri, M., et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399-412.
27. Fingar, D.C., Salama, S., Tsou, C., Harlow, E., and Blenis, J. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472-1487.
28. Manning, B.D., and Cantley, L.C. 2003. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31:573-578.
29. Marr, M.T., D'Alessio, J.A., Puig, O., and Tjian, R. 2007. IRES-mediated functional coupling of transcription and translation amplifies insulin receptor feedback. Genes Dev. 21:175-183.
30. Leibiger, I.B., Leibiger, B., Moede, T., and Berggren, P.O. 1998. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Mol. Cell. 1:933-938.
31. Shima, H., et al. 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17:6649-6659.
32. Pende, M., et al. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24:3112-3124.
33. Majumder, P.K., et al. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10:594-601.
34. Thomas, G.V., et al. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12:122-127.
35. Perren, A., et al. 2000. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157:1097-1103.
36. Wendel, H.G., et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332-337.
37. Hernando, E., et al. 2007. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. 13:748-753.
38. Le Bacquer, O., et al. 2007. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 117:387-396.
39. Barlund, M., et al. 2000. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60:5340-5344.
40. Wood, L.D., et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science. 318:1108-1113.
41. Ma, X.M., Yoon, S.O., Richardson, C.J., Julich, K., and Blenis, J. 2008. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiencey of spliced mRNAs. Cell. 133:303-313 .
42. Dorrello, N.V., et al. 2006. S6K1- and bTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 314:467-471.
43. Aguilar, V., et al. 2007. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab. 5:476-487.
44. Thompson, C.B., et al. 2005. How do cancer cells acquire the fuel needed to support cell growth? Cold Spring Harb. Symp. Quant. Biol. 70:357-362.
45. Salmena, L., Carracedo, A., and Pandolfi, P.P. 2008. Tenets of PTEN tumor suppression. Cell. 133:403-414.
46. Liu, J.L., et al. 2007. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res. 67:11054-11063.
47. Jonkers, Y.M., Ramaekers, F.C., and Speel, E.J. 2007. Molecular alterations during insulinoma tumorigenesis. Biochim. Biophys. Acta. 1775:313-332.
48. Johannessen, C.M., et al. 2008. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 18:56-62.
49. Paul, E., and Thiele, E. 2008. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N. Engl. J. Med. 358:190-192.
50. Lopez, T., and Hanahan, D. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 1:339-353.
51. Pelengaris, S., Khan, M., and Evan, G.I. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:321-334.